Brello and Zepbound: How Its Telehealth Tirzepatide Model Works

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article sits within the PlexusDx Education Hub, our library on GLP-1 therapy, weight management protocols, and the genetics that quietly shape metabolic outcomes. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Brello or its parent company, and no affiliate links or compensation are involved.

People searching Brello alongside Zepbound usually want to know how the telehealth brand handles tirzepatide, the molecule inside Zepbound. This review covers how a compounded-versus-branded decision is made, the program workflow, the pricing signals in the tirzepatide market, and the genetic layer no prescription captures. Fair-balance context, not a buying recommendation, as of April 2026.

Brello and the tirzepatide question

Zepbound is a brand of tirzepatide, a GIP/GLP-1 dual agonist. Brello (Brello Health) operates as telehealth plus a compounded-pharmacy pathway, which means it may route a patient toward an FDA-approved brand product through a retail pharmacy or toward compounded tirzepatide or semaglutide through a 503A compounding pharmacy. The two are legally and factually different, and which one applies depends on the plan and clinical review. Check Brello's official website (search for its current URL when you read this) for how it structures tirzepatide access today.

How a compounded-versus-branded prescription gets decided

Whether a program supplies a branded product or a compounded formulation comes down to clinical judgment, availability, and the plan a patient selects. FDA-approved brand tirzepatide is dispensed through a retail pharmacy; compounded tirzepatide is prepared by a licensed 503A compounding pharmacy where clinically justified and permitted by state rules. Compounded products are not generics and are not identical to the brand. Confirm which pathway any telehealth service uses before you commit.

The telehealth workflow, step by step

Most GLP-1 telehealth programs share a four-part sequence: an intake form capturing weight, medical history, and medication list; a licensed clinician's review and, if eligible, a prescription; routing of that prescription to a retail or compounding pharmacy; and follow-up visits that support titration and manage side effects. Differences show up in provider type, pharmacy partner, and subscription packaging rather than in the core steps.

Pricing signals in the tirzepatide market

Brello posts its pricing on its own site, and totals hinge on the compound, the subscription tier, and whether the product is branded or compounded. Across telehealth GLP-1 programs, monthly spend as of April 2026 generally lands somewhere between roughly $200 and $700 or more, with meaningful variance. These figures shift often, so verify current pricing on Brello's official website before any commitment.

What the SURMOUNT program actually tested

Tirzepatide's evidence base rests on its dual-agonist mechanism, engaging both the GIP and GLP-1 receptors. The core trials are SURMOUNT (tirzepatide for weight management, The New England Journal of Medicine, 2022) and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024); the parallel STEP program (NEJM 2021) established semaglutide for weight management. Trial populations and endpoints differ, and outcomes vary from person to person.

The genetic layer no tirzepatide prescription captures

A telehealth prescription for tirzepatide does not read the genetic terrain it acts on. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene targeted by every compound in the class), MC4R (a melanocortin receptor central to satiety), and TCF7L2 (a transcription factor linked to glucose homeostasis and GLP-1 secretion) map baseline metabolic biology. They are pathway-level markers that do not predict response to any specific compound, yet they describe the system a clinician prescribes into.

PlexusDx provides semaglutide and tirzepatide through its Weight Management Protocols, offered as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The upstream difference is the genetics. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including the FTO, MC4R, and TCF7L2 variants that shape baseline GLP-1, appetite-regulation, and energy-balance biology. That is the test before you invest approach, turning guesswork into an informed conversation with your provider.

Not affiliated: PlexusDx is not affiliated with Brello and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: Alternatives For Zepbound, Buy Zepbound Online, Discount Zepbound, GLP 1 vs Zepbound.

Disclaimer: This article is educational. PlexusDx is not affiliated with Brello and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols, tirzepatide and semaglutide with genetic context most telehealth programs omit. Or start upstream and take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

Does Brello offer Zepbound or compounded tirzepatide?

Telehealth programs in this category may route patients to an FDA-approved brand product through a retail pharmacy or to compounded tirzepatide through a 503A compounding pharmacy, depending on the plan and clinical review. Confirm the exact product and pathway directly with Brello, since branded and compounded tirzepatide are not the same thing.

Is compounded tirzepatide the same as the brand?

No. Compounded tirzepatide is prepared by a licensed 503A compounding pharmacy and is legally and factually distinct from the FDA-approved brand product. It is not a generic. Quality, potency, and sourcing vary by pharmacy, so verify the pharmacy's licensing and the prescriber's oversight before proceeding.

How does the Precision Peptide Genetic Test relate to tirzepatide?

It does not predict how you will respond to tirzepatide or any specific compound. It reads pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, upstream context that applies regardless of which telehealth service prescribes the compound.

How does PlexusDx compare with Brello for tirzepatide?

PlexusDx offers tirzepatide and semaglutide through its Weight Management Protocols and pairs them with the Precision Peptide Genetic Test. The differentiator is pathway-level genetic insight delivered alongside the medication, context that telehealth-only programs like Brello generally do not provide with a prescription.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.